- Conditions
- NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric Cancer (GC), Endometrial Cancer
- Interventions
- TS-104
- Drug
- Lead sponsor
- TwoStep Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 3
- States / cities
- Maumee, Ohio • Portland, Oregon • Fairfax, Virginia
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 3,553
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lung Cancer, Metastatic Cancer
- Interventions
- microarray analysis, mutation analysis, flow cytometry, immunologic technique
- Genetic · Other
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- Not listed
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Prostate Cancer, Bladder Cancer, Non-small Cell Lung Cancer, Esophageal Cancer, Sarcoma
- Interventions
- NY-ESO-1 Plasmid DNA Cancer Vaccine
- Biological
- Lead sponsor
- Ludwig Institute for Cancer Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Dacomitinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 12
- States / cities
- Beverly Hills, California • Los Angeles, California • Washington D.C., District of Columbia + 3 more
- Conditions
- Lung Cancer
- Interventions
- radiation therapy-3 fractions, Radiation therapy-5 fractions
- Device
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2034
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Radiation Therapy, Conventional radiation
- Radiation
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 7
- States / cities
- Austin, Texas • Dallas, Texas • Houston, Texas + 4 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- BNT326, Pumitamig
- Drug
- Lead sponsor
- BioNTech SE
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 880 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Stanford, California • New Haven, Connecticut + 8 more
- Conditions
- Lung Cancer
- Interventions
- Pazopanib
- Drug
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 2
- States / cities
- Chapel Hill, North Carolina • Pittsburgh, Pennsylvania
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Brain Metastases
- Interventions
- Abemaciclib
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 19
- States / cities
- Duarte, California • La Jolla, California • San Francisco, California + 15 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Pembrolizumab, Pemetrexed, Carboplatin, Cisplatin
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Baltimore, Maryland • Detroit, Michigan
- Conditions
- Lung Cancer, Non-Small Cell Lung Cancer
- Interventions
- ABT-751, Placebo, Docetaxel
- Drug
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Burbank, California • Orange, California + 10 more
- Conditions
- Non Small Cell Lung Cancer, EGFR Exon 20 Mutation
- Interventions
- CLN-081
- Drug
- Lead sponsor
- Cullinan Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 284 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 18
- States / cities
- Anaheim, California • Duarte, California • Irvine, California + 12 more
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Pemetrexed, Nivolumab, Ipilimumab
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- Paclitaxel, Carboplatin, Cisplatin, Veliparib, Pemetrexed
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 595 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 25
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Springdale, Arkansas + 21 more
- Conditions
- Lung Cancer
- Interventions
- ZD6474
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Ramucirumab, Paclitaxel, Carboplatin
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • San Francisco, California • Aurora, Colorado + 4 more
- Conditions
- Non-small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, Nsclc, NSCLC Stage IV, Minimal Residual Disease, Non Small Cell Lung Cancer Metastatic
- Interventions
- Local ablative therapy, Blood collection to assess for ctDNA
- Procedure · Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 9
- States / cities
- Hartford, Connecticut • Miami, Florida • Basking Ridge, New Jersey + 6 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- FWD1509 MsOH
- Drug
- Lead sponsor
- Forward Pharmaceuticals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Canton, Ohio • Houston, Texas
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Imatinib Mesylate, Docetaxel
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- gemcitabine HCL, pemetrexed disodium
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer, Triple Negative Breast Cancer
- Interventions
- MM-151, MM-151 + irinotecan
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Lafayette, Indiana • Buffalo, New York + 1 more
- Conditions
- Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer, Melanoma
- Interventions
- XL281, famotidine
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 6
- States / cities
- Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 3 more
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- SID530, Taxotere
- Drug
- Lead sponsor
- SK Chemicals Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 2
- States / cities
- Miami, Florida • Canton, Ohio
- Conditions
- Lung Cancer
- Interventions
- beta-glucan MM-10-001, flow cytometry, laboratory biomarker analysis, questionnaire administration
- Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2021
- U.S. locations
- 1
- States / cities
- Duarte, California